Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial.
Subodh VermaC David MazerDeepak L BhattSatish R RajAndrew T YanAtul VermaEleuterio FerranniniGudrun SimonsJisoo LeeBernard ZinmanJyothis T GeorgeDavid FitchettPublished in: Diabetes care (2019)